137 results about "Mice brain" patented technology

The present invention relates to bifidobacterium breve CCFM1025, its fermented food and application thereof. Bifidobacterium breve CCFM1025 of the present invention can improve the depression-like behavior of depressed mice, increase the levels of 5-hydroxytryptophan, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice, and reduce the levels of 5-hydroxytryptophan in the serum of depressed mice. Corticosterone levels, increased serum 5-hydroxytryptamine levels in depressed mice, improved intestinal flora disturbance in depressed mice, decreased intestinal Veillonellaceae abundance, increased the abundance of Bifidobacteria and Mycoplasmaceae , increase the α-diversity of intestinal flora, reduce the occurrence of inflammatory bowel disease and obesity; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the level of 5-hydroxytryptophan in this cell Secretion, specifically providing precursors for the synthesis of 5-HT in the brain. It has broad application prospects.

The invention relates to bifidobacterium longum subspecies CCFM687, fermented food and application thereof. Bifidobacterium longum infantile subspecies CCFM687 of the present invention can improve the depression-like behavior of depressed mice, improve the levels of 5-hydroxytryptamine, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice; improve depression Butyric acid content in the gut of mice; lower intestinal abundance of Desulfovibrio spp., increased abundance of Bifidobacterium and S24‑7 families, increased gut microbiota α‑diversity, and improved intestinal Intestinal flora disorder, reduce the occurrence of autism, inflammatory bowel disease, obesity and type I diabetes; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the 5-hydroxychromatin level of the cells The secretion of amino acid provides precursor substances for the synthesis of 5-hydroxytryptamine in the brain. Therefore, it has broad application value.

The invention provides a preparation method and application of a PQQ-DA imprinted magnetic nanoparticle, belonging to the field of bioanalysis technology. According to the preparation method, Fe3O4 is used as a core and coated with SiO2; then preparation is carried out so as to obtain the PQQ-DA imprinted magnetic nanoparticle; thus, a PQQ-DA magnetic nanoparticle imprinted material with high recognizability and high selectivity on its surface. After molecular imprinting modification of a magnetic nanoparticle with specificity, the prepared imprinted magnetic nanoparticle has magnetism and specific selectivity to targets and is greatly advantaged in separation, purification and enrichment of medium-and-low-concentration compounds in brain tissue of a complex matrix. The prepared PQQ-DA imprinted magnetic nanoparticle is applied to UPLC-MS determination for analysis of trace PQQ-DA in an organism. According to the invention, UPLC-MS based on molecularly-imprinted solid-phase extraction is established in the invention, can detect the content of trace PQQ-DA in the brain of a mouse and has a detection limit of 0.2 * 10<-11> mg / mL. The PQQ-DA imprinted magnetic nanoparticle has great guidance significance to research on the occurrence and mechanism of neurological diseases.

The invention belongs to the field of biotechnology and cerebral arterial thrombosis, and particularly relates to application of circular RNA circ-FoxO3 in preparation of products for preventing and treating cerebral arterial thrombosis. The circular RNA is highly conservative and has the same reverse shearing site in human-derived or mouse-derived species. The application proves that the circ-FoxO3 is highly expressed in cerebrovascular endothelial cells of a MCAO / R mouse and the cerebrovascular endothelial cell line subjected to OGD / R treatment; A certain effect of the circ-FoxO3 in the endothelial barrier treated by OGD / R is shown by knockdown or over-expression of the circFoxO3. The application of the circular RNA circ-FoxO3 provides a new thought for prevention of hemorrhagic transformation after acute ischemic stroke, and provides a new target for development of a neurovascular protective agent.

The invention relates to a medicine for preventing and treating ischemic stroke. In the mouse cerebral ischemia-reperfusion model, the compound of the present invention can significantly reduce the behavioral score, can significantly reduce the percentage of cerebral infarction / whole brain, and can significantly reduce the water content of ischemia-reperfusion damaged brain tissue, and relieve ischemia. The degree of lateral cerebral hemisphere edema can be used to prevent and treat ischemic stroke.

The invention discloses a breeding method of rabies virus attenuated strains; the method comprises the following steps: using a CTN-181 strain homologous with a strain CTN-1-V for the production of rabies vaccine for Chinese people as a parent strain, and cloning and screening by virtue of in vitro cell line culture, animal in vivo tissue alternate passage and a plaque purification technology; screening neurovirulence in the brains of mice at different day ages so as to obtain two attenuated strains which are respectively named as CTN-1-3 and CTN-1-19; and carrying out amplification, titration, verification and whole genome sequencing to the attenuated strains so as to obtain a CTN-1-3 whole genome sequence as shown in SEQ ID NO:1 and a CTN-1-19 whole genome sequence as shown in SEQ ID NO:2. The attenuated strains disclosed by the invention are low in strain residual virulence, good in immunogenicity and good in genetic stability; the strains have reached or exceeded requirements of World Health Organization (WHO) on the safety and the validity of candidate strains; and the strains are suitable for producing oral live vaccine for rabies.

The invention discloses an enzymatic hydrolysate suitable for mouse brain tissue cell separation in any period and an optimization method for realizing low loss of a single-cell suspension. The proportion of living cells in the single-cell suspension obtained by the method is superior to that of the single-cell suspension obtained by the method in the prior art. Due to the advantages, technicians in the field can complete separation of brain tissue cells of mice in all stages and obtain cell suspension with high motility rate, high yield and low impurity ratio, or the separated cells can be continuously applied to subsequent single cell sequencing experiments, and a more real and meaningful result is obtained. And a more complete guarantee is provided for further clarification of disease mechanisms and treatment of diseases.

The invention belongs to the technical field of pharmacy, and particularly relates to an application of danshinolic acid A in preparation of medicines for preventing and treating AIDS encephalopathy as well as nerve damages caused by an HIV-1Tat protein. According to the invention, an HIV-1Tat protein damage type nerve cell line PC 12 and nerve cells on mouse brain slices are protected by using danshinolic acid A with different concentrations, and the effect of reducing the death of the nerve cells caused by the Tat protein of the danshinolic acid A is respectively detected by an MTT experiment, LDH detection and a Tunnel experiment; and dendritic spines are labeled by scattering Dil gold particles, and the effect of reducing Tat protein damage synaptic connectivity of the danshinolic acid A is detected. Through statistical analysis of experimental results, the danshinolic acid A is found to have a good protection effect against damages of the nerve cells caused by the Tat protein and can be used for preparing the medicines for preventing and treating the nerve damages caused by the Tat protein as well as the AIDS encephalopathy.

The invention discloses a novel application of red stilbene and red stilbene polysaccharide in preparing medicament for treatment of Alzheimer disease. Red stibene and red stilbene polysaccharide in the invention can protect SH-SY5Y cells from the damage from A beta 25-35, and increase the viability of SH-SY5Y cells. The Morris water maze test indicates that red stibene and red stilbene polysaccharide can improve the cognitive dysfunction of mice with rapid brain aging and rats injected with A beta and AD in the hippocampus. Further histology detection indicates that red stilbene and red stilbene polysaccharide can increase the contents of center neurotransmitters 5-HT, 5-HIAA, NE and DA in rapid aging mice brain, wherein the neurotransmitters are monoamines.

The invention discloses an administration method for an experimental animal brain; by adopting a method for burying a catheter into the experimental animal brain, injection to the experimental animal brain is more convenient. According to the administration method, a special successive administration device is adopted, and a mouse or a rat is taken as an experimental animal, and the administration method comprises the following steps: 1, narcotizing the experimental animal with 30 percent of chloral hydrate, fixing the experimental animal on a mouse brain locator, and determining the position of a paracele; 2, burying an administration catheter into the paracele of the experimental animal according to the step, and fixing the catheter to the head of the experimental animal by dental cement when cerebrospinal fluid overflows from the catheter; 3, in 4 days after the catheter is buried successfully, performing successive intramuscular injection every day with 0.2ml of 0.8 million units of penicillin sodium, and diminishing inflammation of the experimental animal; 4, performing administration: sucking up a right amount of to-be-experimented drug solution by a 10mul microinjector, and partially inserting the syringe needle of a microsyringe into the catheter buried into the experimental animal brain, wherein the insertion depth is 0.5-2.0cm, and successive administration can be performed on the mice brain from the catheter.

The invention discloses an application of Hispolon in the improvement of the cognition and memory ability and the reduction of senile plaques. Alzheimer's disease (AD) is a neurodegenerative disease with nerve cell fiber entanglement, amyloid beta-protein (Abeta) plaque deposition and cognition function decline as pathologic characteristics, wherein Abeta extracellular toxic accumulation is considered as one of main attack links of the AD. It is found that the Hispolon can improve the spatial memory learning ability of AD mice and obviously clear amyloid plaques in APP / PS1 double transgenic ADmodel mice brain tissues, which shows that the Hispolon can be applied to the treatment of the AD and the development of related drugs.

The invention discloses application of bifidobacterium breve CCFM1025 in relieving Alzheimer's disease, and belongs to the field of microorganisms. The bifidobacterium breve CCFM1025 can significantly improve cognitive and memory disorder of mice with Alzheimer's disease, reduce the content of A beta 1-42 protein in the brains of the mice with Alzheimer's disease, improve the level of brain-derived neurotrophic factors and postsynaptic density protein in the brains of the mice with Alzheimer's disease, and improve the content of interleukin 6 in the serum of the mice with Alzheimer's disease; and the bifidobacterium breve CCFM1025 can regulate intestinal flora and metabolites thereof. The bifidobacterium breve CCFM1025 can be used for preparing pharmaceutical compositions for relieving dementia and Alzheimer's disease and improving cognitive disorder, can also be used as a microecological preparation to be applied to drugs, fermented food or health care products, and has a very wide application prospect.